Related Experiment Videos

Nrf2: a potential target for new therapeutics in liver disease

A M Bataille1, J E Manautou

  • 1Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.

Clinical Pharmacology and Therapeutics
|August 9, 2012
PubMed

Insights

Nuclear erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant responses, shows promise for treating common liver diseases. Activating Nrf2 may help slow the progression of nonalcoholic fatty liver disease, alcoholic liver disease, and drug-induced liver injury.

Area of Science:

  • Hepatology and molecular biology
  • Oxidative stress research
  • Transcription factor signaling

Background:

  • Nuclear erythroid 2-related factor 2 (Nrf2) is a transcription factor crucial for cellular defense against oxidative stress.
  • Nrf2 regulates the expression of numerous cytoprotective genes.
  • Emerging evidence suggests Nrf2's therapeutic potential in liver disease.

Purpose of the Study:

  • To review the role of Nrf2 in the pathogenesis of common liver diseases.
  • To explore the potential of Nrf2 activation as a therapeutic strategy for liver conditions.
  • To highlight specific disease stages where Nrf2 modulation may be beneficial.

Main Methods:

  • Literature review of studies investigating Nrf2 in liver disease models.
  • Analysis of Nrf2 downstream targets and their role in cytoprotection.
  • Focus on nonalcoholic fatty liver disease/steatohepatitis, alcoholic liver disease, and drug-induced liver injury.

Main Results:

  • Nrf2 activation demonstrates protective effects in various liver injury models.
  • Modulation of Nrf2 pathways can mitigate oxidative stress and inflammation in the liver.
  • Specific therapeutic targets within the Nrf2 pathway are being identified.

Conclusions:

  • Nrf2 is a promising therapeutic target for managing and treating prevalent liver diseases.
  • Targeting Nrf2 activation may offer a novel approach to alleviate liver disease progression.
  • Further research is warranted to translate Nrf2-based therapies into clinical practice.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...